Frazier Lifesciences Acquisition Corporation Logo

Frazier Lifesciences Acquisition Corporation

FLAC

(1.0)
Stock Price

9,87 USD

6.98% ROA

7.31% ROE

17.99x PER

Market Cap.

0,00 USD

0% DER

0% Yield

0% NPM

Frazier Lifesciences Acquisition Corporation Stock Analysis

Frazier Lifesciences Acquisition Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Frazier Lifesciences Acquisition Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-12.1x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

The stock's ROE indicates a negative return (-11.71%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-3.23%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Frazier Lifesciences Acquisition Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Frazier Lifesciences Acquisition Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Unknown
2 MACD Unknown
3 RSI Unknown
4 Stoch RSI Unknown

Frazier Lifesciences Acquisition Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Frazier Lifesciences Acquisition Corporation Revenue
Year Revenue Growth
2020 0
2021 0 0%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Frazier Lifesciences Acquisition Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2020 0
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Frazier Lifesciences Acquisition Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2020 120.884
2021 1.366.281 91.15%
2022 9.054.320 84.91%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Frazier Lifesciences Acquisition Corporation EBITDA
Year EBITDA Growth
2020 -126.807
2021 4.194.685 103.02%
2022 -19.121.044 121.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Frazier Lifesciences Acquisition Corporation Gross Profit
Year Gross Profit Growth
2020 0
2021 0 0%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Frazier Lifesciences Acquisition Corporation Net Profit
Year Net Profit Growth
2020 -126.807
2021 9.739.493 101.3%
2022 -29.067.768 133.51%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Frazier Lifesciences Acquisition Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2020 0
2021 1 0%
2022 -2 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Frazier Lifesciences Acquisition Corporation Free Cashflow
Year Free Cashflow Growth
2021 -138.378
2022 -239.895 42.32%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Frazier Lifesciences Acquisition Corporation Operating Cashflow
Year Operating Cashflow Growth
2021 -138.378
2022 -239.895 42.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Frazier Lifesciences Acquisition Corporation Capital Expenditure
Year Capital Expenditure Growth
2021 0
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Frazier Lifesciences Acquisition Corporation Equity
Year Equity Growth
2020 134.803.107
2021 131.640.454 -2.4%
2022 -11.668.257 1228.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Frazier Lifesciences Acquisition Corporation Assets
Year Assets Growth
2020 139.869.628
2021 139.505.058 -0.26%
2022 139.284.947 -0.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Frazier Lifesciences Acquisition Corporation Liabilities
Year Liabilities Growth
2020 5.066.521
2021 7.864.604 35.58%
2022 12.213.018 35.6%

Frazier Lifesciences Acquisition Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0.55
Price to Earning Ratio
17.99x
Price To Sales Ratio
0x
POCF Ratio
-1266.11
PFCF Ratio
0
Price to Book Ratio
1.33
EV to Sales
0
EV Over EBITDA
-0.29
EV to Operating CashFlow
8.86
EV to FreeCashFlow
8.86
Earnings Yield
0.06
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
9.57
Graham NetNet
-0.37

Income Statement Metrics

Net Income per Share
0.55
Income Quality
-0.03
ROE
0.07
Return On Assets
0.07
Return On Capital Employed
-0.01
Net Income per EBT
2.33
EBT Per Ebit
-3.06
Ebit per Revenue
0
Effective Tax Rate
-1.33

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.02
Return on Tangible Assets
0.07
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,07
Book Value per Share
7,42
Tangible Book Value per Share
7.42
Shareholders Equity per Share
7.42
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.29
Current Ratio
6.7
Tangible Asset Value
0,13 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Frazier Lifesciences Acquisition Corporation Dividends
Year Dividends Growth

Frazier Lifesciences Acquisition Corporation Profile

About Frazier Lifesciences Acquisition Corporation

Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.

CEO
Employee
0
Address
Two Union Square
Seattle, 98101

Frazier Lifesciences Acquisition Corporation Executives & BODs

Frazier Lifesciences Acquisition Corporation Executives & BODs
# Name Age
1 Dr. James N. Topper M.D., Ph.D.
Chief Executive Officer & Chairman
70
2 Mr. David J. Topper
Chief Financial Officer & Director
70
3 Mr. Gordon Empey J.D.
Vice President & Gen. Counsel
70

Frazier Lifesciences Acquisition Corporation Competitors